METHO OF SORBINILE PREPARATION

Prepn. of sorbinil (I), or its pharmaceutically acceptable cationic salt, comprises (i) crystallising the (-)-3-aminomethyl pinane salt (IIa) of (I) from a soln. of racemic hydantoin of formula (III), and (ii) converting (IIa) to (I) or its salt. Alternatively, (a) either the (+)-3-aminomethyl pinan...

Full description

Saved in:
Bibliographic Details
Main Authors MOORE BERNARD S.,US, SYSKO ROBERT J.,US, CUE BERKELEY W. JR.,US, MASSETT STEPHEN S.,US, HAMMEN PHILIP D.,US
Format Patent
LanguageEnglish
Published 12.01.1990
Edition5
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Prepn. of sorbinil (I), or its pharmaceutically acceptable cationic salt, comprises (i) crystallising the (-)-3-aminomethyl pinane salt (IIa) of (I) from a soln. of racemic hydantoin of formula (III), and (ii) converting (IIa) to (I) or its salt. Alternatively, (a) either the (+)-3-aminomethyl pinane salt (IIb) or the (-)-2-amino-2-norpinane salt (IV) of the enantiomer of sorbinil is crystallised from a soln. of the racemic hydantoin of formula (III), (b) a concentrate of sorbinil is isolated from the mother liquor, (c) the quinine salt (V) of (I) is crystallised from a soln. of the concentrate; and (d) the quinine salt is converted to (I) or its salt. Also claimed are chiral amine salts of (I), i.e. (IIa), (IIb), (IV) and (V). (I) is a potent aldose reductase inhibitor, esp. useful in controlling the chronic complications of diabetes mellitus. Process gives good yields with much lower solvent vols., and avoids the use of a highly toxic resolving agent (brucine). The efficacy of the process is further enhanced by isolating and recycling the undesired enantiomer via 6-fluoro-4-chromanone.
Bibliography:Application Number: CS19830008271